CD8A and neoplasm: Using MHC‐I epitopes from two model antigens, ovalbumin (OVA) and tyrosinase‐related protein 2 (Trp2), we demonstrated that this nanovaccine formulation could promote the activation of DCs and trigger a robust antigen‐specific CD8+ T cell response (Scheme 1), resulting in significant tumor inhibition.